New MGA Analysis of the Adalimumab Biosimilars Market in the United States
The Biosimilars Council released the following statement in response to the new MGA report authored by Alex Brill and Christy Robinson.
New PCMA Podcast Highlights Importance of Prescription Drug Rebates
“The rebate rule came out of a concern about rising drug prices,” said Brill. “But it is a policy that is chock full of unintended consequences. If it were implemented, we’d have fewer discounts. That’s definitely not going to lower overall spending in the healthcare sector.”
New White Paper Identifies Patent Thickets as Barrier to US Biosimilars Market and Domestic Manufacturing
“How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing,” authored by Alex Brill and Christy Robinson, explains how reference biologic manufacturers create thickets of overlapping, weaker follow-on patents to keep competitors from entering the market. The paper highlights how originators have strong incentives to protect their profit streams and have found patent thickets to be an easy way to significantly extend the duration of monopolies in the US, preventing access to more affordable medicines for patients.
New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year
Report details five instances of product hopping that collectively cost $4.7 billion annually.
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
- A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax Reform
- New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
- Congress on the Brink of Disrupting the PBM Market
- Raising the Salt Cap Would Increase Tax Complexity
- Economics of “Delinking” Are Still Not Good
- The Child Tax Credit: Tradeoffs and Preferences
- Oregon’s Measure 118: The Turnover Tax Is the Worst
- Dueling Child Tax Credit Proposals: Harris vs. Vance
- Trump Proposes Bringing Back the Deduction for Auto Loan Interest
